Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Labeling Rule Should Be Tweaked, Firms Say; Dems Want It Squashed

Executive Summary

FDA appears to have a relatively smooth task ahead of itself as it works to finalize its proposed rule delineating when firms can change product labels without prior agency approval since the comments supporting the proposal contain few suggested changes

You may also be interested in...



No Dispute Over Safety-Related Label Updates; Does FDA Hold All The Cards?

A new dispute resolution process for product labeling updates may see little action given the drug safety liability pressures from outside FDA, Lauren Silvis, an associate in Sidley Austin's Food and Drug Practice, said

No Dispute Over Safety-Related Label Updates; Does FDA Hold All The Cards?

A new dispute resolution process for product labeling updates may see little action given the drug safety liability pressures from outside FDA, Lauren Silvis, an associate in Sidley Austin's Food and Drug Practice, said

FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act

Tucked away on the sixth floor of the Parklawn Building in Rockville, FDA's Office of Chief Counsel is calm and quiet. Beneath the surface, however, there is a surge of activity. One of the main engines driving the agency, the 80-lawyer shop helps craft regulations, manages dozens of lawsuits and oversees every enforcement action

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel